论文部分内容阅读
目的:探讨依达拉奉对原发性肾病综合征(PNS)患者的治疗作用。方法:50例PNS患者随机分对照组及治疗组。治疗组除加用依达拉奉外,两组其他治疗措施完全相同。对所有患者在治疗前、缓解期进行24 h尿蛋白定量的测定,并观察患者治疗前后脂质过氧化产物丙二醛(MDA)的变化。结果:治疗组经依达拉奉治疗后MDA含量显著降低(P<0．05),治疗组疗效显著优于对照组(P<0．05)。结论:用依达拉奉治疗原发性肾病综合征患者可使MDA显著降低,减少尿蛋白的丢失明显优于对照组(P<0．01)。
Objective: To investigate the therapeutic effect of edaravone on patients with primary nephrotic syndrome (PNS). Methods: Fifty patients with PNS were randomly divided into control group and treatment group. In addition to the treatment group with edaravone, the other two groups of treatment exactly the same. All patients in the treatment, remission 24 h urinary protein was measured and observed before and after treatment of patients with lipid peroxidation product malondialdehyde (MDA) changes. Results: After treatment with edaravone, the content of MDA in the treatment group decreased significantly (P <0.05), and the therapeutic effect in the treatment group was significantly better than that in the control group (P <0.05). Conclusion: Treatment of patients with idiopathic nephrotic syndrome with edaravone significantly decreased MDA and decreased proteinuria (P <0.01).